Treating young patients with breast cancerBMJ 2000; 320 doi: (Published 29 April 2000) Cite this as: BMJ 2000;320:1173
Our system for collecting declarations of competing interests failed partially for this editorial by J M Dixon and G Hortobagyi (19 February, pp 457-8). Because the BMJfailed to send Dr Hortobagyi a form, we did not receive a statement on competing interests from him. His coauthor, however, did receive a form and stated “none declared.” We now have a statement from Dr Hortobagyi (see below). We apologise to him and to readers for our oversight.
“GH has served on ad hoc advisory boards for Genentech, Bristol-Myers Squibb, Novartis, CTI, and Eli Lilly over the past five years. He has received honorariums for public speaking, usually in the context of continued medical education meetings, from Genentech, Bristol-Myers Squibb, Novartis, and Aventis. He or members of his group have received or currently receive research grants fromGenentech, Bristol-Myers Squibb, Novartis, AstraZeneca, and Aventis.”